The estimated Net Worth of Lisa Wright is at least $413 Thousand dollars as of 3 June 2024. Lisa Wright owns over 434 units of Vericel Corp stock worth over $413,009 and over the last 3 years Lisa sold VCEL stock worth over $0.
Lisa has made over 6 trades of the Vericel Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently Lisa exercised 434 units of VCEL stock worth $18,966 on 3 June 2024.
The largest trade Lisa's ever made was exercising 3,200 units of Vericel Corp stock on 1 May 2024 worth over $139,840. On average, Lisa trades about 1,181 units every 96 days since 2021. As of 3 June 2024 Lisa still owns at least 9,451 units of Vericel Corp stock.
You can see the complete history of Lisa Wright stock trades at the bottom of the page.
Lisa's mailing address filed with the SEC is C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 10 years, insiders at Vericel Corp have traded over $9,831,645 worth of Vericel Corp stock and bought 890 units worth $10,297 . The most active insiders traders include Dominick Colangelo, Gerard J Michel, and Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of $567,401. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth $18,700.
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
Vericel Corp executives and other stock owners filed with the SEC include: